A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03695185|
Recruitment Status : Recruiting
First Posted : October 4, 2018
Last Update Posted : May 29, 2020
|Condition or disease||Intervention/treatment||Phase|
|Ulcerative Colitis (UC)||Drug: ABBV-323 Dose A Drug: ABBV-323 Dose B||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy|
|Actual Study Start Date :||March 26, 2019|
|Estimated Primary Completion Date :||December 18, 2020|
|Estimated Study Completion Date :||August 28, 2022|
Participants administered with ABBV-323 dose A IV at Week 0 and ABBV-323 dose B for 12 Weeks. Participants who achieve clinical response may enter the maintenance period in which participants are administered with ABBV-323 dose B
Drug: ABBV-323 Dose A
ABBV-323 Dose A is intravenously (IV) administered.
Other Name: Ravagalimab
Drug: ABBV-323 Dose B
ABBV-323 Dose B is administered subcutaneously (SC).
Other Name: Ravagalimab
- Percentage of Participants with Endoscopic Improvement [ Time Frame: At Week 8 ]Endoscopic Improvement is defined as Mayo endoscopic subscore of 0 or 1.
- Percentage of Participants with Clinical Remission per Adapted Mayo Score [ Time Frame: At Week 8 ]Clinical remission per Adapted Mayo score is defined as stool frequency subscore (SFS) <=1, and not greater than baseline, rectal bleeding subscore (RBS) = 0 , and endoscopic subscore <=1.
- Percentage of Participants with Clinical Response per Adapted Mayo Score [ Time Frame: At Week 8 ]Clinical response per Adapted Mayo score is defined as the decrease from Baseline >= 2 points and >= 30%, PLUS a decrease in RBS >=1 or an absolute RBS <=1.
- Percentage of Participants with Clinical Response per Partial Adapted Mayo Score [ Time Frame: Up to Week 12 ]Clinical response per Partial Adapted Mayo score is defined as decrease from baseline >=1 points and >=30%, PLUS a decrease in RBS >= 1 or an absolute RBS <=1.
- Percentage of Participants with Clinical Remission per Full Mayo Score in Participants with a Full Mayo Score of 6 to 12 at Baseline [ Time Frame: At Week 8 ]Clinical Remission per full Mayo score is defined as Full Mayo score <=2 with no subscore > 1.
- Percentage of Participants with Endoscopic Remission [ Time Frame: At Week 8 ]Endoscopic remission is defined as Mayo endoscopic subscore = 0.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03695185
|Contact: ABBVIE CALL CENTERemail@example.com|
|Study Director:||AbbVie Inc.||AbbVie|